Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
Kanaji N, Ichihara E, Tanaka T, Ninomiya T, Kozuki T, Ishikawa N, Nishii K, Shoda H, Yamaguchi K, Kawakado K, Toyoda Y, Inoue M, Miyatake N, Watanabe N, Inoue T, Mizoguchi H, Komori Y, Kojima K, Kadowaki N.
Kanaji N, et al. Among authors: inoue m, inoue t.
Lung. 2024 Feb;202(1):63-72. doi: 10.1007/s00408-023-00669-9. Epub 2024 Jan 24.
Lung. 2024.
PMID: 38265672
Free PMC article.